JP2019504631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504631A5 JP2019504631A5 JP2018541222A JP2018541222A JP2019504631A5 JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5 JP 2018541222 A JP2018541222 A JP 2018541222A JP 2018541222 A JP2018541222 A JP 2018541222A JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- genetically modified
- immunocompetent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291999P | 2016-02-05 | 2016-02-05 | |
| US62/291,999 | 2016-02-05 | ||
| PCT/US2017/016543 WO2017136748A1 (en) | 2016-02-05 | 2017-02-03 | Compositions and methods for recombinant cxadr expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504631A JP2019504631A (ja) | 2019-02-21 |
| JP2019504631A5 true JP2019504631A5 (enExample) | 2020-03-12 |
Family
ID=59500016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541222A Abandoned JP2019504631A (ja) | 2016-02-05 | 2017-02-03 | 組換えｃｘａｄｒ発現のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190046570A1 (enExample) |
| EP (1) | EP3411474A4 (enExample) |
| JP (1) | JP2019504631A (enExample) |
| KR (1) | KR20180102108A (enExample) |
| CN (1) | CN108884443A (enExample) |
| AU (1) | AU2017214581A1 (enExample) |
| CA (1) | CA3012472A1 (enExample) |
| WO (1) | WO2017136748A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019023269A1 (en) * | 2017-07-25 | 2019-01-31 | California Institute Of Technology | DISCOVERING TROGOCYTOSE MEDIATION EPITOPES |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2021030030A1 (en) | 2019-08-09 | 2021-02-18 | Nantomics, Llc | Machine methods to determine neoepitope payload toxicity |
| CN119876018B (zh) * | 2024-12-16 | 2026-01-30 | 广东志珞生物科技有限公司 | 一种nk细胞及其在制备抗肿瘤药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994132A (en) * | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| AU2001237042A1 (en) * | 2000-02-16 | 2001-08-27 | University Of Massachusetts | Transgenic, non-human animals containing a coxsackie/adenovirus receptor (car) |
| EP1497412A4 (en) * | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS USED IN IMMUNOTHERAPY |
| CN106459916A (zh) * | 2014-06-18 | 2017-02-22 | 乔治-施派尔-豪斯化学疗法研究所 | 作为细胞治疗剂的car‑表达nk‑92细胞 |
-
2017
- 2017-02-03 CA CA3012472A patent/CA3012472A1/en not_active Abandoned
- 2017-02-03 WO PCT/US2017/016543 patent/WO2017136748A1/en not_active Ceased
- 2017-02-03 US US16/073,947 patent/US20190046570A1/en not_active Abandoned
- 2017-02-03 EP EP17748289.0A patent/EP3411474A4/en not_active Withdrawn
- 2017-02-03 JP JP2018541222A patent/JP2019504631A/ja not_active Abandoned
- 2017-02-03 AU AU2017214581A patent/AU2017214581A1/en not_active Abandoned
- 2017-02-03 KR KR1020187022005A patent/KR20180102108A/ko not_active Withdrawn
- 2017-02-03 CN CN201780009615.2A patent/CN108884443A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy | |
| Zhang et al. | Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic | |
| Heidbuechel et al. | Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies | |
| CN110214025B (zh) | 携带双特异性t细胞衔接器的腺病毒 | |
| Jones et al. | Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy | |
| Yu et al. | T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy | |
| JP6754532B2 (ja) | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 | |
| Qiu et al. | Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma | |
| AU2019385665B2 (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l | |
| Vasconcelos et al. | Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine | |
| JP2010527919A5 (enExample) | ||
| CN115243700A (zh) | 治疗性细胞组合物及其制造方法和用途 | |
| Shen et al. | Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance | |
| Erkes et al. | Intratumoral infection with murine cytomegalovirus synergizes with PD-L1 blockade to clear melanoma lesions and induce long-term immunity | |
| CN108396015A (zh) | 编码b7蛋白质的溶瘤腺病毒 | |
| US20200270574A1 (en) | CD1d and TCR-NKT Cells | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| IL293009A (en) | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment | |
| US20220195006A1 (en) | Peptide markers to track genetically engineered cells | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| JP2020524145A5 (enExample) | ||
| JP2022512595A (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| JP2023515471A (ja) | 抑制性キメラ受容体構造物 | |
| Liu et al. | Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models | |
| Han et al. | Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell |